Cargando…
Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer’s disease
BACKGROUND: High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to tre...
Autores principales: | Castello, Michael A, Jeppson, John David, Soriano, Salvador |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236650/ https://www.ncbi.nlm.nih.gov/pubmed/25179671 http://dx.doi.org/10.1186/s12883-014-0169-0 |
Ejemplares similares
-
Moving beyond Aim Three: a need for a transdisciplinary approach to build capacity for economic evaluations in implementation science
por: Barnett, Miya L., et al.
Publicado: (2021) -
Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer’s disease?
por: Murray, Melissa E, et al.
Publicado: (2014) -
Antimicrobial resistance – moving forward?
por: Lomazzi, Marta, et al.
Publicado: (2019) -
‘Treatment resistance’ in electroconvulsive therapy (ECT) patients: time to move on
por: Kellner, C. H., et al.
Publicado: (2019) -
Improving lung cancer survival; time to move on
por: Heuvers, Marlies E, et al.
Publicado: (2012)